Skip to content

Efficacy and mechanisms of specific immunotherapy in the treatment of allergic respiratory inflammation

Efficacy and mechanisms of specific immunotherapy in the treatment of allergic respiratory inflammation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16010142
Enrollment
Unknown
Registered
2016-12-13
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic respiratory inflammation

Interventions

Placebo group:Placebo
Specific immunotherapy group:Dust mite drops

Sponsors

Huashan Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients in Shanghai with 2 or more of the following symptoms (watery anterior rhinorrhea, sneezing, nasal obstruction and nasal pruritis) for > 1 hour on most days, and with edema of inferior turbinate and watery secretion in the common meatus according to anterior and posterior rhinoscopy, and with a positive skin prick test response to dust mite and abnormal serum dust mite specific IgE levels (= 0.35 kU/L), and with ages between 18 and 75, male or female

Exclusion criteria

Exclusion criteria: Allergic rhinitis patients in Shanghai with a negative skin prick test response to dust mite and normal serum dust mite specific IgE levels (< 0.35 kU/L), or with intermittent or persistent moderate to severe asthma, or with long-time treatment of oral H1 antihistamine, or with treatment of systemic corticosteroids within a month, or with chronic obstructive pulmonary disease, or with severe cardiac diseases, or with cirrhosis, or with uremia, or with contraindication of corticosteroids treatment, or with allergy to glycerol, or with pregnancy, or with malignant tumors, or with contraindications of dust mite drops treatment including respiratory infection or inflammation with fever, asthma attack, severe acute or chronic diseases, inflammatory diseases, multiple sclerosis, autoimmune diseases, active period of pulmonary tuberculosis, severe psychiatric disorders, ß blockers for hypertension or glaucoma, angiotensin converting enzyme inhibitor, acute or chronic cardiovascular insufficiency, severe renal insufficiency, or with experiences of participating in other clinical trials within 3 months

Design outcomes

Primary

MeasureTime frame
Rhinoconjunctivitis quality of life questionaire;Visual Analogue Scale;Forced expiratory volume in one second;

Countries

China

Contacts

Public ContactLin Lin

Huashan Hospital of Fudan University

linlinhsn@aliyun.com+86 21 52887802

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026